Ascend & ABL Inc.

ABOUT ASCEND & ABL INC.

60+ years of biologics & government experience
30+ years of AAV research, development & manufacturing
Flexible & scalable technology portfolio for early to late-stage support
Process optimization with right first-time approach using DoE methodology
Onsite filling capabilities in 2 United States locations
Unmatched toolbox of high-end, low-volume analytical methods

Ascend Advanced Therapies-ABL (Ascend-ABL) is a gene-to-GMP CDMO specializing in high-quality, cost-effective gene therapy, immunotherapy, oncolytic, and vaccine development and commercialization. The team of experts is dedicated to complementing extensive in-house knowledge with a suite of next-generation technologies to create transparent and effective partnerships with customers.

From the earliest stages, through to clinical and commercial scales, optimized design, manufacturability, scale-up, and quality assurance are critical components of the support offered. An extensive suite of analytics enables greater success throughout every stage of the process. Even before process development starts, a roster of in-silico tests can be used to screen client targets to identify, mitigate risk, and ensure manufacturability of the product/process. Onsite fill/finish capacity in two United States locations also lowers the time and cost while ensuring the highest quality of drug product.

Partnerships range from working with academia and industry to supporting government innovators and biotech/large pharma. This means that it is necessary for the team to have a deep understanding of regulatory requirements and approval pathways.

Let’s build the future of advanced therapies together! Reach out at business@ascend-adv.com.

INDUSTRY INSIGHTS

Solving The AAV Scalability Challenge

Explore the effectiveness of a flexible, scalable AAV manufacturing platform that incorporates well-characterized bioreactors and advanced production systems to drive the development of cost-effective, high-quality gene therapies.
The Importance Of AAV Process Comparability Throughout Development

Ensure scalability, quality, and regulatory compliance from early development to commercialization for faster, cost-effective gene therapy success by streamlining your viral vector production strategy.
Enhancing AAV Production Using High-Throughput Screens And Rational Design

Learn to leverage cutting-edge technologies and innovative processes to enhance yields, quality, and scalability for next-generation gene therapy development and delivery.
Gene Therapy CDMOs Play Critical Role In Enabling AAV Process Improvement, Standardization

Access innovative, scalable manufacturing solutions and expert CDMO support to accelerate your journey from concept to commercialization.
The Deep Roots Of Gene Therapy In Florida

Discover how Ascend builds on a legacy of AAV innovation in Florida, advancing gene therapy with cutting-edge expertise, GMP manufacturing, and deep academic collaboration.

CONTACT INFORMATION

Ascend & ABL Inc.

9800 Medical Center Dr D

Rockville, MD 20850

UNITED STATES

Request More Information

Visit Our Website

SOLUTIONS

Gene Therapy Manufacturing Support Designed To Optimize Yield, Quality
We provide comprehensive support across serotypes for various capsids, vector sizes, and conformations.
Analytics-Driven AAV Development And Manufacturing
Gain a comprehensive understanding of the biochemical composition of each vector batch while minimizing product consumption, ensuring efficiency and precision in analysis.
Gene Therapy Formulation
We focus on selecting the right buffer and excipient combinations, conducting thorough stability testing, and confirming device compatibility and dosing procedures.
Gene Therapy Innovation From Platform To Process
Our advanced, modular AAV manufacturing platform is continuously evolving to adapt to developer needs and the ever-changing regulatory landscape.
Optimizing AAV Yield And Quality In Gene Therapy Process Development
Utilize our innovative EpyQ™ AAV production system or conventional triple transfection for scalable solutions across all AAV serotypes.
What We Do

Ascend is the partner for AAV vector design, manufacturability, scale-up and quality assurance. From early pre-clinical phases into the clinic and out on the market, we understand that consistent product quality is not negotiable and work to get it right early on. Our team is always thinking about the scalability of a product to ensure it can have the greatest impact on the patients that need it.
Outsourcing: A Way To Help Your Team Overcome Challenges
Partnering with us provides immediate access to a skilled CMC team with decades of experience across serotypes and production scales.

POSTERS

ATLAS: A High-Throughput Screening Platform For Optimizing AAV Production

To overcome manufacturing bottlenecks and reduce the high cost of gene therapies, our ATLAS platform has identified novel factors that boost rAAV9 production over 30-fold.
Development Of A Next-Generation AAV Helper Plasmid With Improved AAV9 Productivity

Enhancing AAV production efficiency is critical for expanding gene therapy applications — this optimized helper construct significantly boosts yield and potency.
Comparing Synthesis Processes To Establish rAAV Batch Quality

In this study, we present a comprehensive analysis of various published and newly developed dsDNA conversion processes that were tested using the same sequencing chemistry.
Targeted CRISPR/Cas9 Screen Identifies Superior HEK293 Cell Lines For AAV9 Production

In this study, we developed a proprietary clonal suspension-adapted HEK293 cell line (AC001.230) through clonal isolation and high-throughput screening, resulting in improved productivity for 7 out of 10 AAV serotypes compared to 293F cells.
High-Throughput Screen Finds Targets To Boost AAV9 Production In HEK293 Cells

Take a look at the potential of this small molecule screening to enhance AAV9 production and improve gene therapy manufacturing efficiency by leveraging novel compounds.